Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca V Negri

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Forensic Sciences|June 13, 2017
Fingerprint Change: Not Visible, But TangibleFrancesca V Negri, Annamaria De Giorgi, Cecilia Bozzetti, et al.
Diagnostic Cytopathology|July 27, 2012
Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samplesCecilia Bozzetti, Francesca V Negri, Cinzia Azzoni, et al.
Anticancer Research|October 15, 2013
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracilFrancesca V Negri, Cinzia Azzoni, Lorena Bottarelli, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 7, 2015
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatmentFrancesca V Negri, Barbara Dal Bello, Camillo Porta, et al.
Critical Reviews in Oncology/Hematology|February 25, 2016
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?Riccardo Giampieri, Marta Caporale, Filippo Pietrantonio, et al.
Oncotarget|September 11, 2016
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenibAndrea Casadei Gardini, Emanuela Scarpi, Luca Faloppi, et al.
Critical Reviews in Oncology/Hematology|June 13, 2017
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?Giuseppe Aprile, Francesca V Negri, Francesco Giuliani, et al.
Oncotarget|August 20, 2016
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectivesValentina Fanotto, Elena Ongaro, Karim Rihawi, et al.
World Journal of Gastrointestinal Oncology|June 2, 2017
Molecular classifications of gastric cancers: Novel insights and possible future applicationsSilvio Ken Garattini, Debora Basile, Monica Cattaneo, et al.
Future Oncology (London, England)|November 10, 2015
Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancerFrancesca V Negri, Pellegrino Crafa, Giuseppe Pedrazzi, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Forensic Sciences|June 13, 2017
Fingerprint Change: Not Visible, But TangibleFrancesca V Negri, Annamaria De Giorgi, Cecilia Bozzetti, et al.
Diagnostic Cytopathology|July 27, 2012
Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samplesCecilia Bozzetti, Francesca V Negri, Cinzia Azzoni, et al.
Anticancer Research|October 15, 2013
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracilFrancesca V Negri, Cinzia Azzoni, Lorena Bottarelli, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 7, 2015
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatmentFrancesca V Negri, Barbara Dal Bello, Camillo Porta, et al.
Critical Reviews in Oncology/Hematology|February 25, 2016
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?Riccardo Giampieri, Marta Caporale, Filippo Pietrantonio, et al.
Oncotarget|September 11, 2016
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenibAndrea Casadei Gardini, Emanuela Scarpi, Luca Faloppi, et al.
Critical Reviews in Oncology/Hematology|June 13, 2017
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?Giuseppe Aprile, Francesca V Negri, Francesco Giuliani, et al.
Oncotarget|August 20, 2016
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectivesValentina Fanotto, Elena Ongaro, Karim Rihawi, et al.
World Journal of Gastrointestinal Oncology|June 2, 2017
Molecular classifications of gastric cancers: Novel insights and possible future applicationsSilvio Ken Garattini, Debora Basile, Monica Cattaneo, et al.
Future Oncology (London, England)|November 10, 2015
Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancerFrancesca V Negri, Pellegrino Crafa, Giuseppe Pedrazzi, et al.
Pageof 2